SynCore Biotechnology Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:SynCore Biotechnology Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10597
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that new drug by research and development management and integration of technology resources. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05; and diagnostic device. Its SB01 drug is a new chemical entity (NCE) that is developed for treating solid tumors, head and neck cancer. SynCore provides SB02 for solid tumors; and SB04 for age-related macular degeneration. The company’s SB05 is a composition of cytostatic drug paclitaxel combined with neutral and positive lipids is being developed for breast cancer; and its marketed product SB03 is an ointment developed for the treatment of external genital warts. SynCore partners with other pharmaceutical companies, non-profit foundation and biotechnology company. The company has its operations in I-Lan and Taipei, Taiwan. SynCore is headquartered in Yilan City, Taiwan.

SynCore Biotechnology Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
SynCore Biotechnology Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 11
Partnerships 12
SynCore Biotech Enters into Co-Development Contract with Aju Pharm 12
National Taiwan University Hospital Forms Joint Venture with SynCore Biotech 13
Licensing Agreements 14
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 14
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 16
Equity Offering 17
SynCore Biotech to Raise USD8.7 Million in Rights Offering of Shares 17
SynCore Biotech to Raise USD1.1 Million in Public Offering of Shares 18
SynCore Biotech to Raise Funds through Public Offering of Shares 19
SynCore Biotech to Raise Funds through Rights Offering of Shares 20
SynCore Biotechnology Co Ltd – Key Competitors 21
SynCore Biotechnology Co Ltd – Key Employees 22
SynCore Biotechnology Co Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Joint Venture 23
Recent Developments 24
Clinical Trials 24
Apr 04, 2017: SynCore Bio is selected to present the Phase I study data of new anti-cancer molecule SB01 at ASCO 2017 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SynCore Biotechnology Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
SynCore Biotechnology Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 11
SynCore Biotech Enters into Co-Development Contract with Aju Pharm 12
National Taiwan University Hospital Forms Joint Venture with SynCore Biotech 13
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 14
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 16
SynCore Biotech to Raise USD8.7 Million in Rights Offering of Shares 17
SynCore Biotech to Raise USD1.1 Million in Public Offering of Shares 18
SynCore Biotech to Raise Funds through Public Offering of Shares 19
SynCore Biotech to Raise Funds through Rights Offering of Shares 20
SynCore Biotechnology Co Ltd, Key Competitors 21
SynCore Biotechnology Co Ltd, Key Employees 22
SynCore Biotechnology Co Ltd, Other Locations 23
SynCore Biotechnology Co Ltd, Joint Venture 23

List of Figures
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
SynCore Biotechnology Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[SynCore Biotechnology Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NTT Communications Corporation:戦略・SWOT・企業財務分析
    NTT Communications Corporation - Strategy, SWOT and Corporate Finance Report Summary NTT Communications Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Franz Haniel & Cie. GmbH:企業の戦略的SWOT分析
    Franz Haniel & Cie. GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Alberici Corp:企業の戦略的SWOT分析
    Alberici Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • IPCA Laboratories Ltd (IPCALAB):企業の財務・戦略的SWOT分析
    Summary IPCA Laboratories Ltd (IPCA) is a pharmaceutical company which manufactures and markets active pharmaceutical ingredients, generics and formulations for various therapeutic areas. The company’s active pharmaceutical ingredients include anti-hypertensive, anti-malarial, diuretic and anthelmin …
  • The Manitowoc Company Inc:企業の戦略・SWOT・財務情報
    The Manitowoc Company Inc - Strategy, SWOT and Corporate Finance Report Summary The Manitowoc Company Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Solstad Farstad ASA (SOFF):石油・ガス:M&Aディール及び事業提携情報
    Summary Solstad Farstad ASA (Solstad), formerly Solstad Offshore ASA is an oil and gas company that provides vessel operation solutions. The company offers carbon footprint, climate neutral network, offshore shipping, green operations, and rainforest protection, documentation programs, and others. I …
  • Toyo Seikan Group Holdings, Ltd.:企業の戦略・SWOT・財務分析
    Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Paramount Resources Ltd (POU):企業の財務・戦略的SWOT分析
    Summary Paramount Resources Ltd (Paramount Resources) is an energy company that offers exploration, production, development, and marketing of oil and gas products. The company offers products such s crude oil, fuel oil, natural gas and natural gas liquids. It operates in three segments such as princ …
  • Sibanye Gold Ltd:戦略・SWOT・企業財務分析
    Sibanye Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Sibanye Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dialog Group Berhad (DIALOG):企業の財務・戦略的SWOT分析
    Dialog Group Berhad (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Pharmstandard:企業の戦略的SWOT分析
    Pharmstandard - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • KemPharm Inc (KMPH):企業の財務・戦略的SWOT分析
    Summary KemPharm Inc (KemPharm) is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company’s product pipeline includes KP415, methylphenidate drug for ADHD; KP201/IR, KP511/ER, KP606/IR and KP746 drugs for the …
  • Deutz AG (DEZ):企業の財務・戦略的SWOT分析
    Deutz AG (DEZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Grohe AG:企業の戦略的SWOT分析
    Grohe AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Eni SpA Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Eni SpA Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Eni SpA (Eni) is an integrated oil and gas company. The company carries out oil and natural gas exploration, field development and production activities. It also involved in supply, trading and shipping of n …
  • MGM China Holdings Ltd:企業の戦略・SWOT・財務情報
    MGM China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary MGM China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • The New Zealand Refining Co Ltd (NZR):石油・ガス:M&Aディール及び事業提携情報
    Summary The New Zealand Refining Co Ltd. (Refining NZ) is an oil refining company that refines and distributes oil products. It operates an oil refinery at Marsden Point in Whangarei, New Zealand. The company processes crude oil types imported from offshore markets and produces refined petroleum pro …
  • Intercept Pharmaceuticals Inc (ICPT):企業の財務・戦略的SWOT分析
    Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Tainergy Tech Co Ltd (4934):電力:M&Aディール及び事業提携情報
    Summary Tainergy Tech Co Ltd (Tainergy) is a renewable energy company that designs, develops, manufactures and markets solar energy products. The company provides products such as solar deionized water systems, multi-crystalline silicon solar cell, standard solar modules, solar module with build in …
  • Stereotaxis Inc (STXS):企業の財務・戦略的SWOT分析
    Stereotaxis Inc (STXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆